TNF and ankylosing spondylitis: A phase 3 multicenter, double-blind, randomized controlled trial was conducted in China to compare the efficacy of IBI303, a biosimilar monoclonal antibody against TNFα, with adalimumab in the treatment of ankylosing spondylitis [65].